Radius Health to Announce Third Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Thursday, November 5, 2020

Rhea-AI Summary

Radius Health (Nasdaq: RDUS) announced the release of its third quarter financial results on November 5, 2020, with a conference call scheduled at 8:30 a.m. ET. Investors can access the call via domestic and international dial-in numbers, with a replay available later the same day. Radius focuses on developing innovative endocrine therapeutics, including its FDA-approved product, TYMLOS, for postmenopausal women with osteoporosis. The company's pipeline includes investigational treatments for osteoporosis in men and hormone-receptor positive breast cancer.

Positive

• The upcoming Q3 financial results release may indicate potential positive financial performance.
• Radius's lead product, TYMLOS, is FDA-approved, tapping into the osteoporosis market.

Negative

• None.

WALTHAM, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 5, 2020. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide a company update.

Conference Call Information:
Domestic Dial-In Number: (866) 323-7965
International Dial-In Number: (346) 406-0961
Conference ID: 9147422

A replay of the conference call will be available on November 5 at 11:30 a.m. ET and live audio webcast of the call will be archived on the Company's website for ninety days. To access the replay, dial (855) 859-2056 U.S. or (404) 537-3406 for International, using conference ID number 9147422. The live audio webcast of the call can be accessed from the Investors section of the Company’s website, https://ir.radiuspharm.com/events-and-presentations. The full text of the announcement and financial results will also be available on the Company’s website.

About Radius

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics. Radius’ lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes the investigational use of abaloparatide injection for the treatment of men with osteoporosis, an investigational abaloparatide-patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer out-licensed to Menarini Group. For more information, please visit www.radiuspharm.com

Investor & Media Relations Contact:
Elhan Webb, CFA
Email: ewebb@radiuspharm.com
Phone: 617-551-4011

FAQ

When will Radius Health announce its Q3 financial results?

Radius Health will release its third quarter financial results on November 5, 2020.

What time is the conference call for Radius Health's Q3 results?

The conference call will take place at 8:30 a.m. ET on November 5, 2020.

How can I access the replay of the Radius Health conference call?

The replay will be available on November 5 at 11:30 a.m. ET, dial 855-859-2056 for U.S. access.

What is Radius Health's lead product?

Radius Health's lead product is TYMLOS (abaloparatide) injection, approved for treating postmenopausal women with osteoporosis.

What other drugs are in Radius Health's pipeline?

The pipeline includes abaloparatide for men with osteoporosis and elacestrant (RAD1901) for hormone-receptor positive breast cancer.